Zelira Therapeutics Limited (ZLDAF)
OTCMKTS
· Delayed Price · Currency is USD
0.2998
+0.0125 (4.35%)
At close: Mar 13, 2025
Zelira Therapeutics Revenue
Zelira Therapeutics had revenue of 655.00 AUD in the half year ending December 31, 2024, a decrease of -99.15%. This brings the company's revenue in the last twelve months to 40.88K, down -85.34% year-over-year. In the fiscal year ending June 30, 2024, Zelira Therapeutics had annual revenue of 94.95K, down -68.47%.
Revenue (ttm)
40.88K AUD
Revenue Growth
-85.34%
P/S Ratio
114.62
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.90M USD
Revenue Chart
* This company reports financials in AUD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Zelira Therapeutics News
- 2 years ago - Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets - PRNewsWire
- 3 years ago - Zelira's Zenivol™, the World's First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany - PRNewsWire
- 3 years ago - Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary - PRNewsWire
- 4 years ago - Zelira Therapeutics Launches HOPE Autism Products In Australia - Benzinga
- 5 years ago - Zelira Study: Cannabis Is A Safe Treatment For Non-Cancer Patients Using Opioids - Benzinga
- 5 years ago - Medical Cannabis Company Zelira's Insomnia Drug Aces Midstage Trial - Benzinga
- 6 years ago - Zelda, Ilera Therapeutics Propose Merger To Form 'One of the World's Leading Medicinal Cannabis Companies' - Benzinga